Recently, Dynavax Technologies Corp. (DVAX) announced the completion of enrollment for the first of three cohorts of patients receiving DV-601 hepatitis B (HBV) therapy in an open-label, dose-escalating early-stage study. The second cohort has been opened for enrollment. All commercial rights to this product are with Dynavax. In the study conducted in Europe, up to 30 patients are to be administered with 6 injections of DV-601 over a period of three months. The study will evaluate the safety and tolerability of DV-601. The company expects to report top-line data from this study in the second half of 2010. HBV affects more than 350 million individuals globally. It is a chronic disease which can lead to cirrhosis of the liver and hepatocellular carcinoma. Currently the global market for HBV therapeutics is estimated at over $1 billion annually and available therapies have limited efficacy. Dynavax to Buy ...

ChromoCure, Inc., a developer and provider of proprietary cancer detection systems, recently announced a co-development agreement with the company’s primary cell preparation and application technology supplier. Under the terms of the agreement, ChromoCure will co-develop a fully integrated chromosomal scanner system for nationwide distribution to pathology and related cancer detection labs.

ChromoCure will collaborate with companies and joint technical research and development efforts to complete a fully automated hybridization system allowing for a complete chromosomal scanning solution. The CS300 system has the ability to perform a full 23-pair chromosomal cross-sectioning for every cell within a sample, while integrating solid tumor incubation equipment for therapeutic and cancer cure protocols testing.

As a leading provider of non-toxic and non-invasive approaches to cancer therapy and cure research, ChromoCure’s systems measure the unique genomic characteristic found in 100 percent of all cancers and never found in normal cells. The company believes its technology is superior and

...

Veritec Moves from Pink Sheets to OTC Bulletin Board

-Veritec, Inc. (OTCBB:VRTC), a pioneer and developer of proprietary two-dimensional matrix technology and developer of mobile banking debit card solutions, today September 4, 2009 announced that its common stock has begun trading on the OTC Bulletin Board (OTCBB). Veritec’s common stock was previously quoted on the Pink Sheets.

“Veritec is very pleased to move from the Pink Sheets to the OTC Bulletin Board,” said Jeff Hattara, President and CEO of Veritec, Inc. “As reflected in our recent press releases, Veritec has had a number of significant commercial achievements in the last few months. We’ve taken this step to increase Veritec’s exposure to investors and improve liquidity in the trading of our common stock as part of our overall strategy to drive value for the company’s shareholders”.

About Veritec, Inc.

Veritec, Inc. is a pioneer and developer of proprietary two-dimensional matrix technology. The company’s portfolio

...

Currently, medicine is, to a large degree, a “one size fits all” proposition. Doctors watch for adverse effects and check personal and family histories. Medical technologies, however, are designed for the general population, not individuals. That’s going to change.

Moreover, there will be huge profit opportunities, in many enabling technologies, for those who invest accordingly. And today I’m going to tell you about a company that will hand you your best chance to make a transformational fortune.

We know that many current treatments work on some people, yet not others. Some drugs are safe for many people, but have dangerous side effects for others. This is because all of us have individual differences in our genetic code based on heredity and environment. Even slight differences can lead to very different reactions to medications.

This has created serious regulatory problems. Drugs are denied regulatory approval not because they do not work, but because some

...

Oncology market is witnessing considerable growth and attracting large investments from many big pharmaceutical companies to increase their presence. Pfizer (PFE) aims big in the oncology market, which is mainly dominated by Roche and expects its global medicine sale for cancer to increase ten-fold by 2018.

The company plans to become the third largest player (from current seventh) in cancer medicine, which contributed about $2.5 billion of sales in 2008. At present, many of its products under clinical trial are for cancer treatment and six more will be added from the acquisition of Wyeth.

A number of factors such as high unmet need, favorable demographics, increased life expectancy and aging population are responsible for the renewed interest in this area. The anti-cancer drug market value is expected to grow to $85 billion in 2013 from $67 billion in 2008. Leading products for cancer therapy (fifth-largest therapeutic class globally) include MabThera/Rituxan, Herceptin

...

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of about 200 entries. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following additional categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete response letter (CRL) re-submissions to the FDA, and pending late-stage pivotal Phase 3 clinical trial results which are designed to support a filing for FDA approval.

On 6/4/09, Abbott Labs [ABT: 45.42, +0.86 (+1.93%)] and AstraZeneca [AZN: 43.34, +1.70 (+4.08%)] announced that the companies have submitted a New Drug Application (NDA) to the FDA for an investigational compound to treat mixed dyslipidemia, a combination of two

...

The rise of individualized medicine is the new direction in oncology. More sophisticated and complex testing will be required to select the right therapy for the right patient at the right time in their treatment. Clarient has created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and diagnostic services available both onsite and over the web. The Company is also developing new, proprietary “companion” diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. Clarient has over 1,700 targeted cancer therapeutics in their pipeline.

Todd S. Barry, M.D., Ph.D. has joined Clarient’s medical staff as Medical Director. Dr. Barry was the Director of Molecular Pathology & Hematopathology for six years at PhenoPath Laboratories, PLLC, a national reference laboratory located in Seattle. Prior to that, he did his Fellowship Training in Hematopathology at the National Cancer Institute. He has also published numerous professional studies and is

...

Nuvelo, Inc. (NUVO) is a biopharmaceutical company that makes drugs for acute cardiovascular and cancer therapy. On September 25, the San Carlos, California-based company announced that it has entered into a definitive merger agreement with privately held ARCA Biopharma, Inc. Under the terms of the agreement, ARCA will become a wholly owned subsidiary of Nuvelo.

The deal will result in the creation of a late-stage biotechnology company which will focus on the treatment of cardiovascular diseases. This deal makes sense for both companies in our view. While Nuvelo will get the chance to transform itself into a late-stage biotech company, ARCA should be able to put NuveloÂ’s significant cash balance to good use towards the commercialization of its lead pipeline candidate, Gencaro, which is currently under FDA review for the treatment of chronic heart failure.

The transaction is expected to close later this year/early next year, subject to customary

...

We are optimistic about Sunesis Pharmaceuticals, Inc.'s (SNSS) lead candidate voreloxin for ovarian cancer and acute myeloid leukemia. However, this candidate is only in phase II trials and competition is tough in the cancer therapy area. Sunesis is still a middle stage clinical development company with relatively week pipeline. This means a high risk for investors.

We are also concerned about the cash position of the company. Since its inception, Sunesis has been incurring operational loss. Sunesis has funded its operations primarily through the issuance of common and preferred stock, research funding, technology access fees and milestone payments from its collaboration partners, debt financings and research grants. We believe Sunesis need to raise additional funds as early as in early 2009. Share offering will certainly dilute current shareholder base, and reduce share price.

Sunesis is now focused on its cancer candidates. It must partner with an established pharmaceutical/biotech company to

...

TapImmune, Inc. (OTCBB: TPIM) announced that their TAP incorporated vaccine for the treatment of cancer was recently reviewed by a third party research article in the Journal of Investigative Dermatology, which confirmed that the company’s vaccine should be considered as a therapy for cancer.

The article, entitled, “Restoration of the Expression of Transporters Associate with Antigen Processing in Human Malignant Melanoma Increases Tumor-Specific Immunity,” was published in advance online on April 3, 2008. TapImmune is a biotechnology company that specializes in the development of immunotherapeutics for cancer and vaccines for infectious diseases, and the company’s stock rose 37.10% in Monday’s trading.

The company’s promising TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells. TAP, which stands for Transporters with Antigen Processing, are proteins responsible for supplying tumor-associated antigens (markers) and viral antigens to the surface of infected cells. Without

...